Neuboron Medical Group Advances Cancer Treatment: Introducing Next-Generation Boron Neutron Capture Therapy
Retrieved on:
水曜日, 4月 10, 2024
Research, Medical Devices, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Neutron, BNCT, Ecosystem, PET, IND, Investigational New Drug, Otorhinolaryngology, Patient, IIT, Clinical trial, National Medical Products Administration, BPA, Medical device, Pharmaceutical industry
Neuboron Medical Group (Neuboron) is pleased to announce significant progress in the commercialization of its comprehensive Boron Neutron Capture Therapy (BNCT) solution, marking a new era in the treatment of refractory tumors.
Key Points:
- Neuboron Medical Group (Neuboron) is pleased to announce significant progress in the commercialization of its comprehensive Boron Neutron Capture Therapy (BNCT) solution, marking a new era in the treatment of refractory tumors.
- On March 26, the Beijing Institute of Medical Device Testing (BIMT) granted Neuboron’s NeuPEX Block-I, an electrostatic accelerator-based BNCT system, its Medical Device Testing Reports.
- This approval facilitates the commencement of Phase-I Clinical Trials targeting recurrent head-and-neck cancer at the Xiamen Humanity Hospital, the premier operational BNCT Center in China.
- This solution encompasses the NeuPEX AB-BNCT System, the NeuMANTA Treatment Planning System, treatment boron drug NBB-001 (BPA), and diagnostic NBB-002 (18F-BPA).